PDCD1 and neoplasm: A recent CRISPR loss‐of‐function screen in tumour cells identified PTPN2 as a top‐hit for the recruitment of T cells and the sensitisation of tumours to anti‐PD‐1 therapy (Manguso et al, 2017; Wiede & Tiganis, 2017).